MeiraGTx Holdings plc (MGTX) fair value analysis
Nasdaq · Updated 2026-10-19
MGTX price how computed
Valuation status
No fair-value estimate yetMGTX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for MGTX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $9.28
- Sector
- Healthcare
- 12-month range
- $6.99–$14.97
- Market cap
- $891M
- From 52-week high
- -38.0%
- Shares outstanding
- 96M
- Rank in Healthcare by quality score
- #90 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
MeiraGTx Holdings plc is a clinical-stage gene therapy company that develops treatments for serious inherited retinal diseases and other genetic eye conditions. The company is headquartered in London, United Kingdom, and maintains operations in the United States and Europe.
MGTX currently ranks #90 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $891M
- P/E (trailing)
- 13x
- Revenue (TTM)
- $398M
- Net margin
- 19.9%
- EPS (TTM)
- $0.71
- Gross margin
- 97.8%
- Debt / equity
- 0.52
- Revenue growth (3-yr avg)
- 2066.3%
- Shares outstanding
- 96M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 23 · oversold
- 50-day average
- $12.51
- 200-day average
- $10.21
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-12
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▲ beat (+538.5%)
2026-03 ▼ miss (-26.7%)
2025-12 ▲ beat (+133.7%)
2025-09 ▼ miss (-26.5%)
2025-06 ▼ miss (-2.1%)
2025-03 ▼ miss (-4.1%)
2024-12 ▲ beat (+10.7%)
2024-09 ▼ miss (-5.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 0 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $27.8
- Target vs last price
- +199.6%
What our data shows for MGTX
- Shares are trading in the lower third of their 12-month price range of $6.99–$14.97.
- The 14-day relative strength index sits at an oversold 23.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MGTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MGTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — MGTX's relative strength index moved into oversold territory this week, shifting from a neutral zone position. This indicator change reflects recent price momentum developments in the Healthcare sector stock. The overall valuation verdict for MGTX remains pending a complete analysis.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — MGTX, a Healthcare sector company, experienced a shift in its RSI zone this week, moving from oversold to neutral territory. This change in TickrTrends' derived indicators reflects a modest technical adjustment in the stock's momentum. The full valuation verdict for MGTX remains awaiting completion.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MGTX stock undervalued?
TickrTrends has no fair-value estimate for MGTX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is MGTX's TickrTrends verdict?
MGTX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does MGTX compare to other Healthcare stocks?
MGTX ranks #90 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MGTX overbought or oversold?
MGTX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does MGTX report earnings next?
MGTX's next earnings report is scheduled for 2026-11-12, per the published earnings calendar.
Does MGTX usually beat earnings estimates?
Over its last 8 reported quarters MGTX beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MGTX?
Of 7 analysts covering MGTX, 7 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $27.8 (+199.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.